StreetAlpha.app
Home › Stocks › LONA

LeonaBio, Inc. (LONA)

Healthcare
$2.02
▼ −17.89%
LAST CLOSE · NOV 20

LeonaBio develops experimental drugs for metastatic breast cancer and ALS, based in Bothell, Washington. It last closed at $2.02 on Nov 20, down 17.89% on the day. The next earnings report for LONA is expected around Thu, Mar 25, 2027, after the close. For the quarter ended Sep 2026, LONA reported EPS of -$0.89. Over its last 5 reports the stock moved an average of 6.2% the session after earnings. Over the last 12 months LONA insiders bought $0 of stock on the open market and sold $99K, according to SEC Form 4 filings.

AI Auto Pilots
Is LONA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LONA.

Key Stats

Last 12 months
Results
Net income
−$156.0M
EPS (diluted)
−$22.20
Valuation
Market cap
$26.4M
13.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$16.3M
At Sep 30
Shareholder equity
$16.0M
Shares outstanding
13.1M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$54.9M−$54.9MFY2021FY2022: −$95.6M−$95.6MFY2022FY2023: −$117.7M−$117.7MFY2023FY2024: −$96.9M−$96.9MFY2024FY2025: −$105.6M−$105.6MFY2025

From LONA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 25
Estimated date · After the close
Reported EPS
-$0.89
Quarter ended Sep 2026
Year ago EPS
-$1.68
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$3.86Dec '24Mar 2025: -$2.34Mar '25Jun 2025: -$1.78Jun '25Sep 2025: -$1.68Sep '25Dec 2025: -$18.90Dec '25Mar 2026: -$1.73Mar '26Jun 2026: -$0.80Jun '26Sep 2026: -$0.89Sep '26Latest -$0.89
Revenue by quarter
Not enough quarters on file yet.
How LONA moved after its last 5 reports
Average move the session after a report ±6.2%
Nov 16, 2026After the close−14.6%
Aug 14, 2026After the close−3.2%
May 7, 2026After the close+1.8%
Mar 26, 2026After the close−7.3%
Nov 6, 2025After the close−4.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on LONAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on LONA: 0 upgrades, 0 downgrades, 0 initiations
MizuhoTarget cut
Nov 21  
Citizens JmpTarget cut
Nov 17  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on LONA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on LONA

Technical Analysis

LONA · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 98% below its 20 day and 141% below its 50 day average. It is 266% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 18), oversold. The nearest support is the 52 week low at $1.91, and the nearest resistance the Pivot at $2.14.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 26.8%/day
Key levels
$14.2152 week high+603.5%
$7.38200 day average+265.3%
$6.37100 day average+215.3%
$5.40Swing high (Oct 29)+167.3%
$4.8850 day average+141.6%
$4.0020 day average+98.0%
$2.37Pivot R1+17.3%
$2.14Pivot+5.9%
$2.02Last close
$1.9152 week low−5.4%
$1.79Pivot S1−11.4%
Indicators
RSI (14)17.77Oversold below 30Oversold
MACD-0.75Below its signal lineBearish
Stochastic4.1Near the bottom of its rangeOversold
ADX (14)28.7Trending down
Williams %R-96.3Oversold below −80, overbought above −20Oversold
CCI (20)-168.9Oversold below −100, overbought above 100Oversold
Rate of change−54.3%Change over 10 sessionsBearish
ATR (14)$0.54Typical daily range, 26.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LONA

What happened before

See how LONA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow LONA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How LONA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for LONAHow many large options trades hit LONA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

LONA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●13 buying vs 12 selling
  • ▲Held by funds +1.7 pts
  • ▲Funds holding +4
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4945+8.9%
In funds' top 1000–
Held by funds60.3%58.6%+1.7 pts
New / increased5 / 87 / 8−13.3%
Reduced / sold out11 / 16 / 3+33.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LONA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LONA Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$99K10 sales · 5 insiders
2026-01 sold $43K2026-03 sold $56KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 4Mark James LittonPRESIDENT and CEOSale5,156$5.37$28K
Mar 4Martin Javier SanChief Medical OfficerSale1,720$5.37$9K
Mar 4Kevin ChurchChief Scientific OfficerSale1,359$5.37$7K
Mar 4Mark WorthingtonGENERAL COUNSEL and CCOSale1,328$5.37$7K
Mar 4Robert RenningerCFOSale906$5.37$5K
Jan 2Mark James LittonPresident and CEOSale2,586$6.88$18K
Every insider buy and sale for LONA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LONA insider trades →

From SEC Form 4 filings by LONA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LONA is in one of them and how their past LONA trades turned out.

LONA in the AI portfolios
Loading…

LONA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LONA in an article yet. Here's the latest on the wider market.

LONA in the news

About LeonaBio

LeonaBio is a biopharmaceutical company based in Bothell, Washington, that develops drug candidates for diseases where current treatments are limited. Its lead candidate, lasofoxifene, is being studied for metastatic breast cancer that has stopped responding well to standard hormone therapy. Its other lead candidate, ATH-1105, is in development for amyotrophic lateral sclerosis, also known as ALS. The company has no approved products yet, and it aims its drugs at patients with these conditions.

Headquarters
Bothell, WA